PEAK6 Investments’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-12,700
Closed -$3.12M 5488
2022
Q3
$3.12M Sell
12,700
-700
-5% -$189K 0.01% 1185
2022
Q2
$3.32M Buy
13,400
+500
+4% +$135K 0.01% 1768
2022
Q1
$4.27M Sell
12,900
-37,500
-74% -$11.5M 0.01% 1220
2021
Q4
$18.1M Sell
50,400
-19,300
-28% -$6.52M 0.04% 452
2021
Q3
$22.7M Buy
69,700
+62,100
+817% +$21M 0.05% 338
2021
Q2
$2.37M Sell
7,600
-8,700
-53% -$2.67M 0.01% 1725
2021
Q1
$5.2M Sell
16,300
-57,500
-78% -$18.4M 0.01% 1029
2020
Q4
$23.9M Buy
73,800
+3,500
+5% +$968K 0.05% 339
2020
Q3
$19.5M Buy
70,300
+25,300
+56% +$7.29M 0.05% 348
2020
Q2
$10.9M Buy
45,000
+37,400
+492% +$7.51M 0.04% 455
2020
Q1
$1.1M Sell
7,600
-28,500
-79% -$4.73M 0.01% 1458
2019
Q4
$6.16M Sell
36,100
-33,200
-48% -$6.16M 0.03% 539
2019
Q3
$12.3M Sell
69,300
-10,100
-13% -$2.18M 0.08% 292
2019
Q2
$20.7M Buy
79,400
+11,600
+17% +$3.08M 0.14% 153
2019
Q1
$19.4M Buy
67,800
+59,400
+707% +$19.7M 0.11% 174
2018
Q4
$2.73M Sell
8,400
-28,100
-77% -$9.76M 0.02% 1010
2018
Q3
$16.4M Buy
+36,500
New +$14.4M 0.07% 287

Other funds holding ABMD

PEAK6 Investments's ABMD Position: Q4 2022 in Review

PEAK6 Investments sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,018 shares — an estimated $496K sold.

PEAK6 Investments first reported a position in ABMD in Q4 2018 and held it in 11 quarters. The position peaked at $8.83M in Q3 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • PEAK6 Investments reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • PEAK6 Investments sold 2,018 Abiomed Inc shares in Q4 2022, an estimated $496K.
  • PEAK6 Investments first reported a position in Abiomed Inc in Q4 2018 and held it in 11 quarters.
  • PEAK6 Investments's Abiomed Inc position peaked at $8.83M in Q3 2019.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.